Why Aehr Test Systems Stock Surged Today
Key Points
Aehr helps semiconductor companies test their products.
Business is booming.
Shares of Aehr Test Systems (NASDAQ: AEHR) rose sharply on Wednesday after the semiconductor equipment maker issued an upbeat artificial intelligence (AI)-fueled growth forecast for the year ahead.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Demand for AI chip testing is surging
Aehr's systems enable chipmakers to stress-test their chips under extreme conditions and identify potential issues earlier in the production process. In this way, Aehr helps to ensure the quality and reliability of a range of semiconductor products while reducing manufacturing costs for its customers.
Perhaps unsurprisingly, given these benefits, demand for Aehr's testing solutions is soaring.
Aehr's net revenue jumped 33% year over year to $18.8 million in its fiscal 2026 fourth quarter, which ended on May 29.
The chip test leader saw record bookings of $60.7 million, more than fivefold the prior-year quarter. That brought its effective backlog to $100.6 million when including bookings that occurred after the quarter's end.
"Demand from AI-related applications continued to accelerate," CEO Gayn Erickson said.
All told, Aehr's adjusted net income improved to $3.6 million, or $0.11 per share, compared to a loss of $0.2 million, or $0.01 per share, in the year-ago period. That was significantly better than Wall Street's estimates, which had called for an adjusted loss of $0.01 per share.
2027 should be another year of impressive growth
Looking ahead, Aehr sees revenue rising by 160% to 200% to between $130 million and $150 million in fiscal 2027, with an adjusted net margin of up to 22%.
Management highlighted AI processors, silicon photonics, and memory chips as potentially powerful growth drivers for its testing solutions.
"With multiple customers entering or expanding production, a record backlog, and additional opportunities under discussion ... we believe Aehr is well positioned for multiple years of strong revenue growth," Erickson said.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.